Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
NGNE 10.21.2024
Drug:NGN-401 NGN-401
Diseases:Rett syndrome
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Child Neurology Society Meeting
Company to host webcast to review data on
Late-breaker poster to be presented during Child Neurology Society Meeting on
These data will also be presented in a late-breaking poster presentation during the 53rd Annual
Neurogene’s Analyst and Investor Webcast/Conference Call
The live webcast and conference call information will be accessible from the Investor Relations section of Neurogene’s website under Events, where the webcast replay will also be available for a limited time.
Neurogene’s CNS Meeting Presentation
- Poster Title:
NGN-401 , a Novel Regulated Gene Therapy for Rett Syndrome: Preliminary Results from the First-in-Human Study - Presenter:
Bernhard Suter , M.D., Medical Director of the Blue Bird Circle Rett Center at Texas Children’s Hospital, Associate Professor of Pediatrics and Neurology atBaylor College of Medicine , and principal investigator in theNGN-401 clinical trial
About NeurogeneThe mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in
View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241018666990/en/
Company:
Source: Neurogene